Brenntag (FRA:BNR) Given a €50.00 Price Target at Warburg Research

Share on StockTwits

Warburg Research set a €50.00 ($58.14) price target on Brenntag (FRA:BNR) in a research report released on Wednesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

BNR has been the topic of a number of other reports. Independent Research set a €46.00 ($53.49) target price on shares of Brenntag and gave the company a neutral rating in a report on Friday, August 9th. Goldman Sachs Group set a €56.00 ($65.12) target price on shares of Brenntag and gave the company a buy rating in a report on Wednesday. UBS Group set a €52.50 ($61.05) target price on shares of Brenntag and gave the company a buy rating in a report on Wednesday. Nord/LB set a €45.00 ($52.33) target price on shares of Brenntag and gave the company a neutral rating in a report on Friday, October 4th. Finally, JPMorgan Chase & Co. set a €50.00 ($58.14) target price on shares of Brenntag and gave the company a buy rating in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of Buy and an average target price of €50.65 ($58.89).

BNR stock opened at €48.25 ($56.10) on Wednesday. Brenntag has a twelve month low of €43.06 ($50.07) and a twelve month high of €56.25 ($65.41). The company’s 50 day moving average is €44.77 and its two-hundred day moving average is €44.28.

About Brenntag

Brenntag AG, a chemical distribution company, purchases and supplies industrial and specialty chemicals in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.

Read More: Trading on Margin

Analyst Recommendations for Brenntag (FRA:BNR)

Receive News & Ratings for Brenntag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brenntag and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.